

## Contents

### Clinical Studies

- 1 SARS-CoV-2 Virus in Cancer Patients: A New Unknown in an Unsolved Equation**  
Martín, M.; Vallejo, C.; López-Campos, F.; Quereda, C.; Muñoz, T.; Sánchez-Conde, M.; Dominguez, J.A.; Soriano, C.; Martín, M.; Suárez-Carantón, C.; Muriel, A.; Garrido, P.; Aceró, J.; Alvarez-Díaz, A.; de la Pinta, C.; Martínez-García, L.; Hernández, R.; Fernández, E.; Alarza, M.; Hervás, A.; Sancho, S. (Madrid)
- 12 Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer**  
Satake, S.; Arigami, T.; Matsushita, D.; Okubo, K.; Shimonosono, M.; Sasaki, K.; Tsuruda, Y.; Tanabe, K.; Mori, S.; Yanagita, S.; Uenosono, Y.; Nakajo, A.; Kurahara, H.; Ohtsuka, T. (Kagoshima)
- 22 Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study**  
Nakazawa, J. (Kagoshima); Tsuruta, N. (Fukuoka); Shimokawa, M. (Fukuoka/Yamaguchi); Kawahira, M.; Arima, S.; Ido, A. (Kagoshima); Koga, F. (Saga); Ueda, Y. (Kumamoto); Komori, A.; Otsu, S. (Oita); Fukuhori, M. (Fukuoka); Makiyama, A. (Fukuoka/Gifu); Taguchi, H. (Kagoshima); Honda, T. (Nagasaki); Shibuki, T. (Saga/Chiba); Nio, K. (Fukuoka/Nagasaki); Ide, Y. (Saga); Ureshino, N. (Saga/Chiba); Mizuta, T. (Saga); Otsuka, T. (Saga/Fukuoka); Shirakawa, T. (Fukuoka/Saga); Mitsugi, K. (Fukuoka/Nagasaki)
- 32 Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma**  
Nagai, H.; Mukouz, T.; Kobayashi, K.; Nogami, A.; Nagumo, H.; Mohri, K.; Watanabe, G.; Amanuma, M.; Yoshimine, N.; Ogino, Y.; Matsui, D.; Daido, Y.; Matsukiyo, Y.; Matsui, T.; Wakui, N.; Momiyama, K. (Tokyo); Higai, K. (Funabashi); Matsuda, T. (Tokyo)
- 41 Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer**  
Kim, H.; Kim, J.Y.; Park, K.U. (Daegu)

### Oncology and Informatics – Research Article

- 49 The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study**  
Kim, T.-W.; Hwang, S.W. (Seoul); Kim, K.O. (Daegu); Cha, J.M. (Seoul); Joo, Y.-E. (Gwangju); Cho, Y.-S. (Seoul)

### Research Articles

- 59 Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer**  
Ando, T. (Toyama); Hosokawa, A. (Toyama/Miyazaki); Sakumura, M.; Motoo, I.; Kajiura, S.; Hirano, K.; Miwa, T.; Yokota, T.; Nakada, N.; Ueda, Y.; Ueda, A.; Tsukada, K.; Ogawa, K. (Toyama); Nakaya, A. (Toyama/Takaoka); Teramoto, A.; Nanjo, S.; Miura, H.; Fujinami, H.; Fujii, T.; Yasuda, I. (Toyama)

Cover illustration  
© S. Karger AG, Basel



© 2023 S. Karger AG, Basel

Access to full text and tables of contents,  
including tentative ones for forthcoming issues:  
[www.karger.com/ocl](http://www.karger.com/ocl)

- 69 The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer**  
Kasajima, M.; Igawa, S.; Manaka, H.; Yamada, K.; Akazawa, Y.; Manabe, H.; Yagami, Y.; Yamamoto, H.; Ito, H.; Kaizuka, N.; Nakahara, Y.; Sato, T.; Mitshufuji, H.; Yokoba, M.; Kubota, M.; Sasaki, J.; Naoki, K. (Sagamihara)

**77 Erratum**